I recently attended the co-sponsored Genitourinary Cancers Symposium. As usual, it was somewhat of a “firehose to take a drink” scenario with great presentations, more posters than you could possibly absorb, and lots of progress on many fronts.
I remember when there were only about 50 “GU oncologists” 30 years ago, and about 300 attended this meeting when it first started. The attendance is now 2,900 from around the world. As one of my patients likes to put on his blog—“help is on the way,” which is really encouraging. There is more to report than I can possibly do in a blog, so I will just poach from existing Internet info and highlight some of the existing posts.
Chemotherapy for newly diagnosed patients with many metastases is now the “standard of care” following the CHAARTED trial that I previously discussed. The French completed a smaller study that did NOT show an advantage for using docetaxel “up front.” There are a number of possible explanations that you can read about here. Not mentioned in that discussion is a moderately complex explanation that came up in the discussion period after the presentation. It turns out that androgen deprivation therapy (ADT) leads to changes in the way docetaxel is metabolized. Thus, the approval of the use of docetaxel in the setting of castrate-resistant prostate cancer (which has been the usual situation) is different from using docetaxel when a patient hasn’t been on ADT for very long. The French study had more toxicity, and potentially more delays in treatment, but the relationship of when the ADT started may have been different from the CHAARTED trial and could explain differences. Nevertheless, CHAARTED was larger, and I think the trial still sets a new standard.
The optimal duration of ADT when given to enhance radiation was covered extensively by Anthony D’amico. The details are pretty complex, and if you want to wade into these weeds, you can start with his JCO article. Basically, the issue is this: ADT helps radiation therapy be more effective. But, it is clearly “toxic” in terms of quality of life and possibly increases cardiac events in men with a history of heart disease.
Both of these factors make it questionable to use at all in men with “low intermediate risk” disease, and we would certainly like to use it for as little time as necessary to get the benefit so that quality of life is preserved. In the higher-risk patients, there is no doubt that it should be used, but the duration is still up for discussion, with the existing “definitive” study showing 36 months is better than six months. Generally, in such patients, I go over this, and then say, “Let’s see how well you tolerate ADT before we reach any final decision on how long to continue.” Certainly a minimum of four months is required, and possibly the longer the better, but I suspect 36 months is too long; and really no one has taken into account the factor that a single three-month GnRH injection can result in quite variable overall duration of testosterone suppression with older men generally not recovering as quickly as the younger guys.
On the vaccine front, data were presented on Prostvac in combination with the immune checkpoint inhibitor, ipilimumab. The exciting findings in using checkpoint inhibitors (including the PD1 and PDL1 drugs used in other diseases) has lagged somewhat in prostate cancer because it isn’t clear that the ongoing immune response is very good. (For example ipilimumab alone in prostate cancer didn’t work.) However, given the promising data on using Prostvac in the phase II trials, the phase III trial has now accrued all of its patients, and we await the result.
Meanwhile, investigators have begun to look at whether adding a checkpoint inhibitor to a vaccine can make further headway. An abstract presented at the meeting reported on the early results of this approach. Dr. Singh from the NCI GU oncology team stated, “In a Phase 1 combination study of 30 mCRPC patients with similar baseline characteristics (predicted median OS of 18.5 months), patients were treated with PROSTVAC plus escalating doses of ipilimumab. The observed median OS was 31.3 months for all dose cohorts and 37.2 months for patients treated at 10 mg/kg based on updated overall survival data. Furthermore, there appears to be a tail on the curve with approximately 20% of patients at 10 mg/kg alive at 80 months.” This certainly means that if the Phase III trial of Prostvac leads to approval by the FDA, there will quickly be more studies of how to make this vaccine even more effective.
Many of us have been talking at this meeting and other recent meetings about a “kitchen sink” approach combining all of the newer drugs to get a biochemical complete response in metastatic patients and then using a vaccine to “clean up” the microscopic disease that is clearly left behind.
I’m looking forward to these trials, which are probably a year or two away, but optimism abounds. Example: A new man with metastatic disease who had prostate radiation or surgery five years ago is found because of a rising PSA. We do fancy scans with C-11 acetate or choline, radiate the known disease, treat with second-generation ADT plus docetaxel x 6, then use the vaccine with a checkpoint inhibitor. (Read that link by the way—terrific.)
Given that prostate cancer is generally a “slow cancer,” there are many men alive today with lurking metastases that will only become apparent five or 10 years from now. These guys will almost certainly be able to take advantage of such an approach—never fast enough, but never more promising prospects, either.
This post originally was published on prost8blog, a blog to help patients and their families understand various aspects of prostate cancer, and is reprinted with permission of Dr. Glodé.